CompePharma View: Strong quarters, narrow foundations

The headline numbers flatter the structure

Read the third-quarter releases side by side and the growth is real. Arcutis reported ZORYVE revenue of $143.9 million, up 45% on a year ago and 11% on the second quarter, and raised full-year net product sales guidance to $535 million to $545 million. BioCryst posted $174.8 million of ORLADEYO revenue and an operating profit of $53.3 million. Innoviva's specialty business grew U.S. net product sales 45% to $43.3 million. Keenova lifted full-year guidance on stronger XIAFLEX growth and a solid Acthar Gel.

Now look at what sits underneath. Arcutis's product revenue is ZORYVE. BioCryst's quarter is almost entirely ORLADEYO: $174.8 million of $180.3 million in total net revenue. Acthar Gel and XIAFLEX together account for $391 million of Keenova's $550 million in continuing net sales, roughly 71%. Zymeworks raised its 2026 revenue range to $337 million to $351 million from $278 million to $292 million, and the release ties its royalty opportunity and a $250 million U.S. approval milestone to a single approval, Ziihera in first-line GEA.

My position is simple. This is a season of excellent execution on narrow bases, and the industry should be honest that narrowness, not growth, is the variable that decides how durable these results are.

Organogenesis is the warning label

Organogenesis reported third-quarter net revenue of $45.5 million against $150.5 million a year earlier. Advanced Wound Care revenue fell 73%. The company swung from net income of $21.6 million to a net loss of $29.6 million. We make no claim here about the cause beyond what the company reported. The point is the shape of the outcome. When the core line breaks, there is no other line to absorb it, and a profitable quarter becomes a loss-making one within a year.

The healthy companies in this group are not immune to that logic. They are simply on the right side of it for now. BioCryst's own release shows the tell: it maintained ORLADEYO guidance at $625 million to $645 million while raising total revenue guidance to $715 million to $730 million. The core brand's outlook did not move. The upside came from elsewhere, and the release does not make that the main story.

The strongest counter-argument

Focus is how small and mid-sized companies win. Arcutis has grown quarter on quarter and generated $18.9 million of operating cash flow in the same period. Spreading resources across weaker assets to look diversified would be worse than concentrating on a product that is clearly working. Keenova's merger synergies are ahead of plan, and its XIAFLEX pipeline, with a plantar fibromatosis sBLA expected in the first quarter of 2027 and a Phase 3 hammer toe study enrolling, shows concentration can be paired with line extension.

That is fair, and it is also the answer. The winners here are not diversifying for its own sake. They are extending the franchise they have: BioCryst with ORLADEYO pellets, now approved for patients aged 12 and older, and a specialty pharmacy transition; Keenova with new XIAFLEX indications; Arcutis with a vitiligo readout due in the fourth quarter. Innoviva takes a different route, pairing a growing specialty business with a royalty stream of $58.1 million in the quarter and a $125 million buyback program. Concentration is defensible when the extensions are visible and funded. It is not defensible when the plan is to hope.

What it means

Investors and partners will increasingly separate quarters that came from a repeatable engine from quarters that came from an event. Zymeworks's raise is mostly a milestone story. Its release notes a Roche collaboration on ZW209 that preserves long-term economics while limiting R&D spend. That is the kind of structure that reduces single-point exposure without diluting focus. Leaders should assume their own results will be read the same way.